BOS-475 / Boston Pharma - LARVOL DELTA

Study to Evaluate the Safety and Antipsoriatic Efficacy of BOS-475 in a Psoriasis Plaque Test (clinicaltrials.gov) - P1; N=15; Completed; Sponsor: Boston Pharmaceuticals; Active, not recruiting ➔ Completed

Clinical • Trial completion

Study to Evaluate the Safety and Antipsoriatic Efficacy of BOS-475 in a Psoriasis Plaque Test (clinicaltrials.gov) - P1; N=15; Active, not recruiting; Sponsor: Boston Pharmaceuticals; Not yet recruiting ➔ Active, not recruiting

Clinical • Enrollment closed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Topical Administration of BOS-475 in Healthy Subjects and Patients With Psoriasis (clinicaltrials.gov) - P1; N=20; Completed; Sponsor: Boston Pharmaceuticals; Active, not recruiting ➔ Completed

Clinical • Trial completion

Study to Evaluate the Safety and Antipsoriatic Efficacy of BOS-475 in a Psoriasis Plaque Test (clinicaltrials.gov) - P1; N=15; Not yet recruiting; Sponsor: Boston Pharmaceuticals

Clinical • New P1 trial

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Topical Administration of BOS-475 in Healthy Subjects and Patients With Psoriasis (clinicaltrials.gov) - P1; N=20; Active, not recruiting; Sponsor: Boston Pharmaceuticals; Recruiting ➔ Active, not recruiting; N=60 ➔ 20

Clinical • Enrollment change • Enrollment closed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Topical Administration of BOS-475 in Healthy Subjects and Patients With Psoriasis (clinicaltrials.gov) - P1; N=60; Recruiting; Sponsor: Boston Pharmaceuticals; Trial completion date: Sep 2019 ➔ Feb 2020; Trial primary completion date: Sep 2019 ➔ Feb 2020

Clinical • Trial completion date • Trial primary completion date